Login / Signup

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.

Junsik ParkKyung Jin EohEun Ji NamSunghoon KimSang-Wun KimYoung-Tae KimJung-Yun Lee
Published in: Yonsei medical journal (2020)
Bevacizumab-containing NAC might be safe and provide longer PFS than chemotherapy alone in patients with advanced ovarian cancer. However, further study is necessary to investigate the impact of bevacizumab-containing NAC on OS.
Keyphrases